Aug 20 (Reuters) - Albany Molecular Research Inc:
* Says received a warning letter from FDA
* Says warning letter does not restrict production or shipment of products from
the facility
* In connection with FDA's inspection of co's pharmaceutical manufacturing
facility in Burlington in March
* Until violations are corrected, Burlington facility may be subject to
additional regulatory action- filing
* Says intends to respond fully, and in a timely manner, to the FDA's warning
letter
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Says received a warning letter from FDA
* Says warning letter does not restrict production or shipment of products from
the facility
* In connection with FDA's inspection of co's pharmaceutical manufacturing
facility in Burlington in March
* Until violations are corrected, Burlington facility may be subject to
additional regulatory action- filing
* Says intends to respond fully, and in a timely manner, to the FDA's warning
letter
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.